HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX:13) announces that regulatory filings for ORPATHYS® (savolitinib) in combinati...
Late-Breaking P4 study, simultaneously published in NEJM, shows CT guidance delivers matched one-year clinical outcomes with shorter procedures, demonstrat...
Biopharma Boardroom speaks with Hubert Martens, CEO of Salvia BioElectronics, about the development of the MySalvia System, an investigational implantable ...
InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced that...
Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company," Stock Code: 9887.HK) announced that the first patient with systemic lupus erythematosus ...
Efficacy signals suggesting improvements in pain scores were observed in Phase 2 clinical studies in postherpetic neuralgia (PHN), fibromyalgia (FM), a...
As demand for Exatecan-based antibody-drug conjugates (ADCs) grows, securing reliable manufacturing capacity and diversified supply chains has become a pri...
Appian (Nasdaq: APPN) and PSI CRO announced the launch of their first joint AI-powered process orchestration solution. The new offering automates clin...
– Etentamig is a second-generation BCMA-directed bispecific antibody T-cell engager with a clinical profile and dosing schedule that can pote...
OTXL-101, a promising therapy in development for a severe, rare pediatric metabolic condition, becomes the first pipeline program to be in-licensed by Or...
CellsBin®, a biotechnology company pioneering Rare-Cell Biology™, announced that it has received a Direct-to-Phase II Small Business Innov...
Astellas Pharma Inc. [TSE: 4503, President and CEO: Naoki Okamura, "Astellas"] and Audax Biosciences Pty Ltd ("Audax") announced that they have ent...
GrOwnValve GmbH, a Berlin-based medical technology company developing personalized heart valves from patients' own tissue, announced the achievement of t...
ASTRIDE trial for first-line ES-SCLC demonstrated favorable median overall survival in serplulimab with chemotherapy versus atezo...
© 2026 Biopharma Boardroom. All Rights Reserved.
